Single CRISPR Treatment Halves 'Bad' Cholesterol for a Year in Early Trial

A first-in-human Phase 1 clinical trial, with findings published in the New England Journal of Medicine and presented by Cleveland Clinic, demonstrated that a single infusion of an experimental CRISPR-Cas9 gene-editing therapy led to approximately 50% reductions in LDL ('bad') cholesterol and triglycerides that lasted for a full year in patients with difficult-to-treat lipid disorders. The study reported no serious adverse events related to the therapy during the one-year follow-up.